CN107936119B - 凝血酶结合抗体分子及其用途 - Google Patents

凝血酶结合抗体分子及其用途 Download PDF

Info

Publication number
CN107936119B
CN107936119B CN201711384542.3A CN201711384542A CN107936119B CN 107936119 B CN107936119 B CN 107936119B CN 201711384542 A CN201711384542 A CN 201711384542A CN 107936119 B CN107936119 B CN 107936119B
Authority
CN
China
Prior art keywords
thrombin
antibody molecule
antibody
exosite
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201711384542.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107936119A (zh
Inventor
詹姆斯·安德鲁·亨廷顿
特雷弗·巴格兰
乔纳森·兰当
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CN107936119A publication Critical patent/CN107936119A/zh
Application granted granted Critical
Publication of CN107936119B publication Critical patent/CN107936119B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201711384542.3A 2011-12-14 2012-12-14 凝血酶结合抗体分子及其用途 Expired - Fee Related CN107936119B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1121513.4A GB201121513D0 (en) 2011-12-14 2011-12-14 Thrombin-binding antibody molecules and uses thereof
GB1121513.4 2011-12-14
CN201280061294.8A CN104053673B (zh) 2011-12-14 2012-12-14 凝血酶结合抗体分子及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280061294.8A Division CN104053673B (zh) 2011-12-14 2012-12-14 凝血酶结合抗体分子及其用途

Publications (2)

Publication Number Publication Date
CN107936119A CN107936119A (zh) 2018-04-20
CN107936119B true CN107936119B (zh) 2021-06-15

Family

ID=45560465

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711384542.3A Expired - Fee Related CN107936119B (zh) 2011-12-14 2012-12-14 凝血酶结合抗体分子及其用途
CN201280061294.8A Expired - Fee Related CN104053673B (zh) 2011-12-14 2012-12-14 凝血酶结合抗体分子及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280061294.8A Expired - Fee Related CN104053673B (zh) 2011-12-14 2012-12-14 凝血酶结合抗体分子及其用途

Country Status (34)

Country Link
US (5) US9518129B2 (https=)
EP (2) EP2791177B1 (https=)
JP (2) JP6216954B2 (https=)
KR (1) KR102114506B1 (https=)
CN (2) CN107936119B (https=)
AU (2) AU2012351858B2 (https=)
BR (1) BR112014014605A2 (https=)
CA (1) CA2856656C (https=)
CO (1) CO7101192A2 (https=)
CY (1) CY1119599T1 (https=)
DK (1) DK2791177T3 (https=)
ES (1) ES2642718T3 (https=)
GB (1) GB201121513D0 (https=)
HK (1) HK1246326A1 (https=)
HR (1) HRP20171775T1 (https=)
HU (1) HUE034793T2 (https=)
IL (1) IL232797B (https=)
LT (1) LT2791177T (https=)
ME (1) ME02901B (https=)
MX (2) MX376876B (https=)
MY (1) MY170980A (https=)
NO (1) NO2791177T3 (https=)
PE (2) PE20190171A1 (https=)
PH (1) PH12014501169B1 (https=)
PL (1) PL2791177T3 (https=)
PT (1) PT2791177T (https=)
RS (1) RS56510B1 (https=)
RU (2) RU2642276C2 (https=)
SG (1) SG11201402560WA (https=)
SI (1) SI2791177T1 (https=)
SM (1) SMT201700580T1 (https=)
UA (1) UA116531C2 (https=)
WO (1) WO2013088164A1 (https=)
ZA (1) ZA201403836B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201310949D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Binding Motif
GB201310948D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Screening methods
CN107043423B (zh) * 2016-02-05 2021-02-26 江苏恒瑞医药股份有限公司 凝血酶抗体、其抗原结合片段及医药用途
EP3412688A4 (en) * 2016-02-05 2019-12-04 Jiangsu Hengrui Medicine Co., Ltd. THROMBIN ANTIBODY, ANTIGENBINDING FRAGMENT, AND PHARMACEUTICAL USE THEREOF
WO2018081534A1 (en) * 2016-10-28 2018-05-03 President And Fellows Of Harvard College Assay for exo-site binding molecules
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
WO2020003077A1 (en) * 2018-06-25 2020-01-02 Janssen Pharmaceutica Nv Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1501812A (zh) * 2000-05-15 2004-06-02 ʷ��˿�������ȳ�ķ���޹�˾ 抗血栓剂
CN1599624A (zh) * 2001-10-29 2005-03-23 苏诺尔分子公司 抑制血液凝固的抗体及其使用方法
WO2010033167A2 (en) * 2008-09-18 2010-03-25 Archemix Corp. Anti-thrombin aptamer formulations and methods for use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011297A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5240913A (en) 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
CA2082643A1 (en) 1990-05-10 1991-11-11 Jan H. Nuijens Inhibitors of factor xii activation and applications thereof
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5443827A (en) * 1993-05-03 1995-08-22 President And Fellows Of Harvard College Fibrin-targeted inhibitors of thrombin
AU1378495A (en) * 1993-12-27 1995-07-17 Hamilton Civic Hospitals Research Development, Inc. Methods and compositions for inhibiting thrombogenesis
GB9613718D0 (en) 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
WO2001000667A2 (en) 1999-06-29 2001-01-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-thrombin peptide from anopheles albimanus salivary gland
CA2378473A1 (en) * 1999-07-23 2001-02-01 The Regents Of The University Of California Modulation of platelet activation
AU2001286900A1 (en) 2000-08-31 2002-03-13 Cor Therapeutics, Inc. Therapeutics and diagnostics based on a novel signal transduction system in platelets
EP1411964A4 (en) * 2001-07-06 2006-06-14 Oregon Health Science Universi PEPTIDES MODULATING BLOOD COAGULATION AND METHODS OF USE
BRPI0614961A2 (pt) 2005-08-26 2016-09-13 Archemix Corp aptâmero, método, e, composição
EP2001504A2 (en) 2006-03-15 2008-12-17 Emory University Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor
WO2009154461A1 (en) 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
ES3005912T3 (en) 2011-07-22 2025-03-17 Csl Behring Gmbh Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
US9518128B2 (en) * 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1501812A (zh) * 2000-05-15 2004-06-02 ʷ��˿�������ȳ�ķ���޹�˾ 抗血栓剂
CN1599624A (zh) * 2001-10-29 2005-03-23 苏诺尔分子公司 抑制血液凝固的抗体及其使用方法
WO2010033167A2 (en) * 2008-09-18 2010-03-25 Archemix Corp. Anti-thrombin aptamer formulations and methods for use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Activation-induced Exposureof the Thrombin Anion-binding Exosite;Qingyu Wu 等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;19940204;第269卷(第5期);第3725-3730页 *
Autoantibody Directed Against Human Thrombin Anion-binding Exosite in a Patient With Arterial Thrombosis: Effects on Platelets, Endothelial Cell, and Protein C Activation;Emmanuel Arnaud 等;《blood》;19940915;第84卷(第6期);第1843-1850页 *

Also Published As

Publication number Publication date
KR20140105556A (ko) 2014-09-01
RU2017144629A (ru) 2019-02-18
MX2014007170A (es) 2015-04-17
PE20141706A1 (es) 2014-11-13
ZA201403836B (en) 2015-12-23
SMT201700580T1 (it) 2018-01-11
CO7101192A2 (es) 2014-10-31
GB201121513D0 (en) 2012-01-25
UA116531C2 (uk) 2018-04-10
NZ625386A (en) 2017-03-31
JP2015501830A (ja) 2015-01-19
SI2791177T1 (en) 2018-03-30
CN104053673A (zh) 2014-09-17
DK2791177T3 (en) 2017-12-18
HUE034793T2 (en) 2018-02-28
EP2791177A1 (en) 2014-10-22
IL232797A0 (en) 2014-07-31
US20190276558A1 (en) 2019-09-12
CN107936119A (zh) 2018-04-20
EP3275903A1 (en) 2018-01-31
US20180334511A1 (en) 2018-11-22
ES2642718T3 (es) 2017-11-17
HRP20171775T1 (hr) 2017-12-29
CA2856656C (en) 2021-01-19
WO2013088164A1 (en) 2013-06-20
BR112014014605A2 (pt) 2017-06-13
PL2791177T3 (pl) 2018-03-30
SG11201402560WA (en) 2014-06-27
AU2012351858A1 (en) 2014-06-12
KR102114506B1 (ko) 2020-05-22
MX376876B (es) 2025-03-07
HK1246326A1 (en) 2018-09-07
AU2017268655B2 (en) 2019-05-09
RU2017144629A3 (https=) 2021-04-05
HK1202564A1 (en) 2015-10-02
MY170980A (en) 2019-09-23
JP6216954B2 (ja) 2017-10-25
US20140370008A1 (en) 2014-12-18
PH12014501169A1 (en) 2014-09-08
CA2856656A1 (en) 2013-06-20
US10287363B2 (en) 2019-05-14
LT2791177T (lt) 2017-11-27
US20170066842A1 (en) 2017-03-09
US20210371543A1 (en) 2021-12-02
RU2642276C2 (ru) 2018-01-24
CN104053673B (zh) 2018-01-12
RS56510B1 (sr) 2018-02-28
PH12014501169B1 (en) 2014-09-08
US9988463B2 (en) 2018-06-05
PE20190171A1 (es) 2019-02-01
AU2017268655A1 (en) 2017-12-21
US9518129B2 (en) 2016-12-13
NO2791177T3 (https=) 2018-02-03
CY1119599T1 (el) 2018-04-04
IL232797B (en) 2018-07-31
PT2791177T (pt) 2017-11-29
JP6705785B2 (ja) 2020-06-03
ME02901B (me) 2018-04-20
EP2791177B1 (en) 2017-09-06
AU2012351858B2 (en) 2017-10-05
RU2014124985A (ru) 2016-02-10
JP2018039798A (ja) 2018-03-15
MX353281B (es) 2018-01-08

Similar Documents

Publication Publication Date Title
CN107936119B (zh) 凝血酶结合抗体分子及其用途
US11155637B2 (en) Thrombin-binding antibody molecules and uses thereof
WO2014202992A1 (en) Screening methods for thrombin binding agent and uses of thrombin binding agent for inhibiting or preventing coagulation
HK1202564B (en) Thrombin-binding antibody molecules and uses thereof
NZ625386B2 (en) Thrombin-binding antibody molecules and uses thereof
WO2014202993A1 (en) Binding motif for thrombin inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210615